US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prospect Capital Corp

25.06

+0.0000

Volume:- -

Turnover:319.71K

Market Cap:9.22B

PE:68.17

High:25.06

Open:25.06

Low:25.06

Close:25.06

Loading ...

Overview Company News Filings

Press Release: United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025

Here’s Why Planet Labs PBC (PL) Shares Rebounded in Q4

Prospect Capital Corp (PSEC) Q2 2025 Earnings Call Highlights: Strong Liquidity and Secured ...

Q2 2025 Prospect Capital Corp Earnings Call

Thomson Reuters StreetEvents

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025

Craig-Hallum Sticks to Their Buy Rating for Planet Labs PBC (PL)

3 Top AI-Powered Biotech Stocks to Buy in February

Planet Labs PBC call volume above normal and directionally bullish

United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Planet Labs PBC Is Maintained at Buy by Goldman Sachs

United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial

Planet Labs PBC (PL) Upgraded to ‘Buy’ by Craig-Hallum After $230M Contract Win and AI-Powered Forest Monitoring Launch

Planet Labs PBC (PL) Secures $230M Deal to Expand Pelican Satellites and Advance AI Capabilities

Cantor Fitzgerald Keeps Their Buy Rating on Planet Labs PBC (PL)

GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan

JMP Securities Sticks to Its Buy Rating for Planet Labs PBC (PL)

GENFIT Announces 2025 Financial Calendar

Planet Labs PBC: Strategic Contract Win and Pelican Constellation to Propel Future Growth

Is Planet Labs PBC (PL) Outperforming Other Computer and Technology Stocks This Year?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PBC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","market":"US","secType":"STK","nameCN":"Prospect Capital Corp","latestPrice":25.06,"timestamp":1640811600000,"preClose":25.06,"halted":4,"volume":0,"delay":0,"floatShares":0,"shares":367817926,"eps":0.367626,"marketStatus":"Delisted","change":0,"latestTime":"04-02 19:13:47 EDT","open":25.06,"high":25.06,"low":25.06,"amount":319705.1613,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.367626,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743638400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":25.06,"dividendRate":0.028731,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","floatShares":0,"roa":"4.83%","roe":"4.16%","lyrEps":0.394789,"shares":367817926,"dividePrice":0.72,"high":25.06,"amplitude":0,"preClose":25.06,"low":25.06,"week52Low":25,"pbRate":"2.90","week52High":26.49,"institutionHeld":0,"latestPrice":25.06,"eps":0.367626,"divideRate":0.028731,"volume":0,"delay":0,"ttmEps":0.367626,"open":25.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512067201","title":"Press Release: United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512067201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512067201?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:04","pubTimestamp":1739966640,"startTime":"0","endTime":"0","summary":"United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025. SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.----February 19, 2025--. United Therapeutics Corporation  announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation . Our public benefit purpose is to provide a brighter future for patients through  the development of nove","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU1571399168.USD","UTHR","BK4139","BK4532","PBC"],"gpt_icon":0},{"id":"2510237787","title":"Here’s Why Planet Labs PBC (PL) Shares Rebounded in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2510237787","media":"Insider Monkey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510237787?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:49","pubTimestamp":1739368140,"startTime":"0","endTime":"0","summary":"Conestoga CapitalAdvisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. For the second consecutive year, U.S. equity indices ended the year with double-digit returns after generating modest returns in the fourth quarter of 2024. Conestoga's investment plans were hindered by the enthusiasm for everything artificial intelligence  related, which the firm believes led to a more speculative investing climate. The Conestoga Small Cap Composite surged 1.67%  in the fourth quarter compared to the Russell 2000 Growth Index’s 1.70% return. The Conestoga SMid Cap Composite returned -0.68%  trailing the Russell 2500 Growth Index’s 2.43% return. The Conestoga Micro Cap Composite advanced 9.91%  vs the Russell Microcap Growth Index’s return of 11.55%. Finally, the Conestoga Mid Cap Composite returned -4.63%  underperforming the Russell Midcap Growth Index’s 8.14% return. Please check the top 5 holdings of the fund for a b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-planet-labs-pbc-pl-134900126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4123","PL","PBC"],"gpt_icon":1},{"id":"2510497113","title":"Prospect Capital Corp (PSEC) Q2 2025 Earnings Call Highlights: Strong Liquidity and Secured ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2510497113","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510497113?lang=en_us&edition=fundamental","pubTime":"2025-02-12 15:08","pubTimestamp":1739344138,"startTime":"0","endTime":"0","summary":"Net Investment Income : $86.4 million or $0.20 per common share for the December quarter.Net Asset Value : $3.4 billion or $7.84 per common share as of December 31.Net Debt to Total Assets: 28.1% as of December 31.Unsecured Debt Plus Unsecured Preferred: 91.9% of total debt plus preferred.Portfolio Fair Value: $7.1 billion as of December.First-Lien Debt: 64.9% of portfolio at fair value, up 620 basis points from the prior year.Second-Lien Debt: 10.2% of portfolio at fair value, down 530 basis points from the prior year.Subordinate Structured Notes: 5.8% of portfolio at fair value, down 210 basis points from the prior year.Unsecured Debt and Equity Investments: 19.1% of portfolio at fair value.Interest Income: 91% of total investment income for the December quarter.Payment in Kind Income: $20 million for the December quarter, down 39% from the prior quarter.Investment Originations: $135 million for the December quarter, with $120 million in first-lien senior secured loans.Prospect Capit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prospect-capital-corp-psec-q2-070858240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSEC","PBC"],"gpt_icon":0},{"id":"2510316231","title":"Q2 2025 Prospect Capital Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2510316231","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510316231?lang=en_us&edition=fundamental","pubTime":"2025-02-12 13:04","pubTimestamp":1739336670,"startTime":"0","endTime":"0","summary":"John Barry; Chairman of the Board, Chief Executive Officer; Prospect Capital Corp. Kristin Van Dask; Chief Financial Officer, Chief Compliance Officer, Treasurer, Secretary; Prospect Capital Corp. M. Grier Eliasek; President, Chief Operating Officer, Director; Prospect Capital Corp. Hello and welcome to the Prospect Capital second fiscal quarter earnings relief and conference call.  As a reminder, this conference is being recorded. I would now like to hand the call to John Barry, Chairman and CEO. Please go ahead.Thank you, MJ. Joining me on the call today are Grier Eliasek, our President and Chief Operating Officer, and Kristin Van Dask, our Chief Financial Officer. Kristin.Thanks, John. Over the past two decades, Prospect Capital Corporation has invested $11.7 billion in over 300 exited investments that have earned a 13% unlevered investment level gross cash IRR to Prospect Capital Corporation. This more-than-two-decade time period includes the GFC and has been dominated in general b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q2-2025-prospect-capital-corp-050430087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","PSEC"],"gpt_icon":0},{"id":"2510886345","title":"GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886345","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510886345?lang=en_us&edition=fundamental","pubTime":"2025-02-10 14:30","pubTimestamp":1739169000,"startTime":"0","endTime":"0","summary":"In conjunction with the royalty financing deal with HealthCare Royalty  announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes:. to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternatively. to pay a consent fee of EUR 0.60 per bond still outstanding after the upcoming bondholder meeting and cancellation of the repurchased 2025 OCEANEs. Both proposals are subject to approval of the royalty financing by the 2025 OCEANEs bondholders at the upcoming bondholders meeting and closing of the royalty financing. Lille , Cambridge , Zurich , February 10, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the final terms of the 2025 OCEANEs repurchase proposal and the consent fee that would be paid to the holders of 2025 OCEANEs still outstanding after cancellation of repurchased 2025 OCEANEs.Concurrently wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-final-terms-dual-063000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","GNFTF","GNFT","USA","CCA","BK4139"],"gpt_icon":0},{"id":"2509784847","title":"GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509784847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509784847?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:10","pubTimestamp":1738876200,"startTime":"0","endTime":"0","summary":"2 new ACLF clinical trials expected to initiate in 1Q25. 3 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT Phase 2 trial. Data of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS-mutated cholangiocarcinoma, to support dose selection for Phase 2. Lille , Cambridge , Zurich , February 6, 2025-GENFIT ,a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today outlines the design of new clinical trials within its Acute on-Chronic Liver Failure  pipeline, with several clinical data readouts by end of 2025.This integrated approach ensures a comprehensive foundation to advance our ACLF pipeline. Notably, it has provided the rationale for including a subset of patients with AD at a high-risk of progressing to ACLF in our target population for the new trials. Broadening inclusion criteria to cover the ACLF continuum creates opportunities to add","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-outlines-anticipated-clinical-trial-211000282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFT","BK4139","GNFTF","PBC","BK4081","HE","USA","CCA"],"gpt_icon":0},{"id":"2509279336","title":"Craig-Hallum Sticks to Their Buy Rating for Planet Labs PBC (PL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509279336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509279336?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:49","pubTimestamp":1738849763,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Jeff Van Rhee maintained a Buy rating on Planet Labs PBC (PL – Research Report) today. The company’s shares closed yesterday a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-planet-labs-pbc-pl-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-planet-labs-pbc-pl-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC","PL"],"gpt_icon":0},{"id":"2509724092","title":"3 Top AI-Powered Biotech Stocks to Buy in February","url":"https://stock-news.laohu8.com/highlight/detail?id=2509724092","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509724092?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:45","pubTimestamp":1738849500,"startTime":"0","endTime":"0","summary":"Artificial intelligence is poised to revolutionize a lot of areas, including medicine.AbbVie, Gilead Sciences, and Moderna have been embracing AI in their R&D processes.Two of the companies have been strong performers lately, while the other could be a turnaround.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/06/3-top-ai-powered-biotech-stocks-to-buy-in-february/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["PBC","ARCH","BK4006","BK4156"],"gpt_icon":0},{"id":"2509461003","title":"Planet Labs PBC call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2509461003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509461003?lang=en_us&edition=fundamental","pubTime":"2025-02-05 01:05","pubTimestamp":1738688706,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Planet Labs (PL) PBC with 12,852 calls trading, 3x expected, and implied vol increasing almost 2 points to 100.15%....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/planet-labs-pbc-call-volume-above-normal-and-directionally-bullish-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/planet-labs-pbc-call-volume-above-normal-and-directionally-bullish-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4123","PL","PBC"],"gpt_icon":0},{"id":"2508645864","title":"United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2508645864","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508645864?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:00","pubTimestamp":1738670400,"startTime":"0","endTime":"0","summary":"Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression. SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 04, 2025----United Therapeutics Corporation , a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyvaso  inhalation solution  for the treatment of idiopathic pulmonary fibrosis .Further, open label extension data published in 2023 showed these improvements in FVC were sustained for at least 64 weeks. For those patients who received placebo during the INCREASE study, marked improvements in FVC were observed following transition to nebulized Tyvaso during the open-label extension study. These data points, combined with substantial preclinical evidence of antifibrotic activity of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/united-therapeutics-corporation-announces-full-120000413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","QID","BK4593","LU1571399168.USD","BK4532","UTHR","FVC","LU1699723380.USD","BK4139"],"gpt_icon":0},{"id":"2508812667","title":"Planet Labs PBC Is Maintained at Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2508812667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508812667?lang=en_us&edition=fundamental","pubTime":"2025-02-04 01:46","pubTimestamp":1738604760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2025 12:46 ET (17:46 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PL","PBC"],"gpt_icon":0},{"id":"2508112330","title":"United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112330","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112330?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"First-ever human clinical trial of a xeno-organ intended to allow for potential registration through the submission of a Biologics License Application to the U.S. FDA. First xenotransplant is expected to occur around mid-year 2025. SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 03, 2025----United Therapeutics Corporation , a public benefit corporation, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug application  to initiate a clinical study of the company’s investigational UKidney derived from a 10 gene-edited source pig. The study will enroll an initial cohort of six end-stage renal disease  patients, expanding to up to 50 participants, and is intended to support a Biologics License Application  with the FDA.United Therapeutics expects the first xenotransplant in this trial to be performed around mid-year 2025.ESRD patients who have been assessed and determined to be ineligible for a conventional allogeneic kidney trans","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/united-therapeutics-corporation-announces-fda-120000505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PBC","LU1571399168.USD","LU1699723380.USD","UTHR","BK4532"],"gpt_icon":0},{"id":"2507937296","title":"Planet Labs PBC (PL) Upgraded to ‘Buy’ by Craig-Hallum After $230M Contract Win and AI-Powered Forest Monitoring Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2507937296","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507937296?lang=en_us&edition=fundamental","pubTime":"2025-01-31 16:57","pubTimestamp":1738313826,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 AI News Updates Trending on Wall Street.In this article, we are going to take a look at where Planet Labs PBC  stands against the other AI stocks.The emerging, cost-effective Chinese AI alternatives have prompted US President Donald Trump to say it is a wake-up call to Silicon Valley. He sees the launch of AI models like DeepSeek r1 and Qwen 2.5 as opportunities rather than threats, given that these innovations can help US companies drive down R&D and deployment costs.Semiconductor manufacturers, satellite imagery, IT consultation, and cybersecurity firms continue to heavily integrate AI to reduce operational costs, introduce process transparency, offer global connectivity, and fortify data protection technologies for growth and optimal business productivity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/planet-labs-pbc-pl-upgraded-085706752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","PL"],"gpt_icon":0},{"id":"2507713066","title":"Planet Labs PBC (PL) Secures $230M Deal to Expand Pelican Satellites and Advance AI Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2507713066","media":"Insider Monkey","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507713066?lang=en_us&edition=fundamental","pubTime":"2025-01-31 02:02","pubTimestamp":1738260149,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Important AI News and Ratings for Today.In this article, we are going to take a look at where Planet Labs PBC  stands against the other AI stocks.In the rapidly shifting landscape of artificial intelligence, the recent market developments have raised important questions about the future of the tech sector. As new players like DeepSeek emerge, the role of AI technologies and their potential to disrupt established companies has become a hot topic. Industry experts, including Greg Fleming, president and CEO of Rockefeller Capital Management, are examining how these changes might affect investment strategies and the broader market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/planet-labs-pbc-pl-secures-180229249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","PL","BK4123"],"gpt_icon":0},{"id":"2507628595","title":"Cantor Fitzgerald Keeps Their Buy Rating on Planet Labs PBC (PL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2507628595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507628595?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:06","pubTimestamp":1738242388,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Colin Canfield from Cantor Fitzgerald maintained a Buy rating on Planet Labs PBC (PL – Research Report), with a pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-keeps-their-buy-rating-on-planet-labs-pbc-pl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-keeps-their-buy-rating-on-planet-labs-pbc-pl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC","PL"],"gpt_icon":0},{"id":"2507614578","title":"GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2507614578","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507614578?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:40","pubTimestamp":1738222800,"startTime":"0","endTime":"0","summary":"GENFIT signs royalty financing deal with HealthCare Royalty  providing up to 185 million non-dilutive capital:. 130 million upfront, with eligibility to receive up to 55 million in two additional instalments based on near-term milestones. Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting. Financing would extend cash runway beyond the end of 2027, assuming drawdown of all instalments. Proceeds to further strengthen the development of the ACLF pipeline. In return, HCRx will receive a portion of royalties on global1 sales of Iqirvo  payable to GENFIT under its licensing agreement with Ipsen, up to an agreed upon cap after which all future royalties will revert back to GENFIT. GENFIT retains rights to all future regulatory, commercial and sales-based milestone payments from Ipsen under the Ipsen agreement. GENFIT to concurrently propose a repurchase of the 2025 OCEANEs aiming to completely eliminate GENFIT’s convertible debt overhang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-non-dilutive-royalty-074000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFT","USA","CCA","GNFTF","BK4139","PBC"],"gpt_icon":0},{"id":"2507615282","title":"JMP Securities Sticks to Its Buy Rating for Planet Labs PBC (PL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2507615282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507615282?lang=en_us&edition=fundamental","pubTime":"2025-01-30 14:26","pubTimestamp":1738218417,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Trevor J. Walsh reiterated a Buy rating on Planet Labs PBC (PL – Research Report) today and set a price target of $6.50. The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-its-buy-rating-for-planet-labs-pbc-pl-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-its-buy-rating-for-planet-labs-pbc-pl-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC","PL","JMP"],"gpt_icon":0},{"id":"2507665944","title":"GENFIT Announces 2025 Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2507665944","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507665944?lang=en_us&edition=fundamental","pubTime":"2025-01-30 05:10","pubTimestamp":1738185000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , January 29, 2025 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025.Publication of revenue and cash position at December 31, 2024. Publication of Full Year 2024 financial statements  The 2024 Universal Registration Document and Annual Financial Report , as well as the Annual Report on Form 20-F will be made public by the end of April 2025.This press release contains certain forward-looking statements, including those w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-2025-financial-calendar-211000875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFT","BK4139","GNFTF","PBC","USA","CCA"],"gpt_icon":0},{"id":"2507265056","title":"Planet Labs PBC: Strategic Contract Win and Pelican Constellation to Propel Future Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2507265056","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507265056?lang=en_us&edition=fundamental","pubTime":"2025-01-30 03:55","pubTimestamp":1738180511,"startTime":"0","endTime":"0","summary":"Needham analyst Ryan Koontz maintained a Buy rating on Planet Labs PBC (PL – Research Report) today and set a price target of $8.00. Ryan Koontz’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/planet-labs-pbc-strategic-contract-win-and-pelican-constellation-to-propel-future-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/planet-labs-pbc-strategic-contract-win-and-pelican-constellation-to-propel-future-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC","CSTA.U"],"gpt_icon":0},{"id":"2507630772","title":"Is Planet Labs PBC (PL) Outperforming Other Computer and Technology Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507630772","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507630772?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:40","pubTimestamp":1738161608,"startTime":"0","endTime":"0","summary":"Investors interested in Computer and Technology stocks should always be looking to find the best-performing companies in the group. Has Planet Labs PBC  been one of those stocks this year?Let's take a closer look at the stock's year-to-date performance to find out.Planet Labs PBC is a member of our Computer and Technology group, which includes 608 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.Based on the most recent data, PL has returned 35.2% so far this year. Meanwhile, stocks in the Computer and Technology group have gained about 34% on average. This means that Planet Labs PBC is outperforming the sector as a whole this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/planet-labs-pbc-pl-outperforming-144008231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PL","TWLO","PBC"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":142}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-12-30","symbol":"PBC","reason":null,"defaultRemindTime":1640874600000,"announcedDate":"2021-12-01","type":"delisting","dateTimestamp":1640840400000},{"market":"US","date":"2021-11-30","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1638282600000,"name":"Prospect Capital Corp","recordDate":"2021-12-15","payableDate":"2021-12-01","currency":"USD","type":"dividend","dateTimestamp":1638248400000},{"market":"US","date":"2021-08-31","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1630416600000,"name":"Prospect Capital Corp","recordDate":"2021-09-15","payableDate":"2021-09-01","currency":"USD","type":"dividend","dateTimestamp":1630382400000},{"market":"US","date":"2021-05-28","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1622208600000,"name":"Prospect Capital Corp","recordDate":"2021-06-15","payableDate":"2021-06-01","currency":"USD","type":"dividend","dateTimestamp":1622174400000},{"market":"US","date":"2021-02-26","symbol":"PBC","amount":0.4296875,"name":"Prospect Capital Corp","recordDate":"2021-03-15","payableDate":"2021-03-01","currency":"USD","type":"dividend","dateTimestamp":1614315600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBC\",market:\"US\",,,undefined,":[{"executeDate":"2019-02-28","recordDate":"2019-03-01","paymentDate":"2019-03-15","value":0.4774306,"currency":"USD"},{"executeDate":"2019-08-29","recordDate":"2019-08-30","paymentDate":"2019-09-15","value":0.4296875,"currency":"USD"},{"executeDate":"2019-11-27","recordDate":"2019-11-29","paymentDate":"2019-12-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":"2020-03-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-05-29","recordDate":"2020-06-01","paymentDate":"2020-06-15","value":0.4296875,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBC\",market:\"US\",delay:false,,,undefined,":{}}}